DexCom Inc (DXCM)vsENvue Medical Inc. (FEED)
DXCM
DexCom Inc
$86.23
-0.07%
HEALTHCARE · Cap: $33.72B
FEED
ENvue Medical Inc.
$0.45
+46.48%
HEALTHCARE · Cap: $3.31M
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 257906% more annual revenue ($4.97B vs $1.93M). DXCM leads profitability with a 20.1% profit margin vs 0.0%. DXCM earns a higher WallStSmart Score of 74/100 (B).
DXCM
Strong Buy74
out of 100
Grade: B
FEED
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+90.0%
Fair Value
$680.73
Current Price
$86.23
$594.50 discount
Intrinsic value data unavailable for FEED.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Trading at 12.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bull Case : FEED
The strongest argument for FEED centers on Price/Book, Debt/Equity.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : FEED
The primary concerns for FEED are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
DXCM profiles as a mature stock while FEED is a value play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.42 — expect wider price swings.
DXCM is growing revenue faster at 13.1% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (74/100 vs 30/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
ENvue Medical Inc.
HEALTHCARE · MEDICAL DEVICES · USA
ENvue Medical Inc. (FEED) is a pioneering healthcare technology company that specializes in the development of cutting-edge medical devices and integrated software solutions aimed at enhancing patient care management. By leveraging innovation to optimize health outcomes and streamline recovery processes, ENvue is well-positioned to capitalize on substantial growth opportunities within the dynamic healthcare landscape. With a strong product pipeline and strategic collaborations, the company represents a compelling investment for institutional investors interested in the future of medical devices and digital health advancements.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?